Regimen Reference Order – H&N – DOCEtaxel

ARIA: H&N – [DOCEtaxel]

Planned Course:Every 21 days until disease progression or unacceptable toxicityIndication for Use:Squamous Cell Carcinoma Head and Neck; Recurrent

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than 1.5 x 10⁹/L AND Platelets equal to or greater than 100 x 10⁹/L ↔ Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements			
Drug	Dose	CCMB Administration Guideline	
dexamethasone	8 mg	Orally twice daily the day before DOCEtaxel treatment and one dose the morning of DOCEtaxel treatment	
		(Self-administered at home)	
		*Nursing Alert: Notify physician if patient has not taken dexamethasone. dexamethasone is prescribed to prevent infusion reactions	

Treatment Regimen – H&N – DOCEtaxel				
Establish primary solution 500 mL of: normal saline				
Drug	Dose	CCMB Administration Guideline		
DOCEtaxel	75 mg/m ²	IV in normal saline 250 mL over 1 hour, following the administration rates below:		
		• Administer at 100 mL/hour for 15 minutes, then		
		Administer remaining volume over 45 minutes		
		Use non-DEHP bags and non-DEHP administration sets		
		OR		
		For 500 mL bags (when Pharmacy must prepare DOCEtaxel in 500 mL normal saline for concentration-dependent stability):		
		IV in normal saline 500 mL over 1 hour, following the administration rates below:		
		Administer at 200 mL/hour for 15 minutes, then		
		Administer remaining volume over 45 minutes		
		Use non-DEHP bags and non-DEHP administration sets		
normal saline	100 mL	ONLY for patients with a PORT		
		IV over 12 minutes		
		*Nursing Alert: This volume is to be administered after standard flush		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'



REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, liver enzymes and electrolytes as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O₂ saturation) at baseline and as clinically indicated
- No observation period is required. Patient can be discharged from treatment room if stable whether they had a reaction or not

Recommended Support Medications			
Drug	Dose	CCMB Administration Guideline	
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting	

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

• Not applicable

